Mass spectrometry and peptide-based vaccine development

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 6, 2007, Pages 644-652

  Ovsyannikova, I G ^a   Johnson, K L ^b   Bergen III, H R ^a,b   Poland, G A ^a  

^a MAYO CLINIC   (United States)

^b DEPARTMENT OF UROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; HEPATITIS B VACCINE; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 4; MEASLES VACCINE; MYCOBACTERIUM VACCINE; NUCLEOCAPSID PROTEIN; PEPTIDE; PHOSPHOPROTEIN; PROTEIN P2; STREPTOCOCCUS VACCINE; VACCINE; VACCINIA VACCINE;

ACCURACY; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG IDENTIFICATION; FRACTIONATION; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; ISOTOPE LABELING; MASS SPECTROMETER; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PEPTIDE ANALYSIS; PERFORMANCE; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEOMICS; REVIEW; T LYMPHOCYTE; TANDEM MASS SPECTROMETRY; TH1 CELL; TH2 CELL; VACCINE PRODUCTION; VACCINIA VIRUS;

ANIMALS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; ISOTOPES; MEASLES VIRUS; PEPTIDES; TANDEM MASS SPECTROMETRY; VACCINES; VACCINIA VIRUS; VIRAL VACCINES;

EID: 36148930239     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100389     Document Type: Review

References (89)

1. Poland, G.A., Ovsyannikova, I.G., Johnson, K.L. & Naylor, S. The role of mass spectrometry in vaccine development. Vaccine 19, 2692-2700 (2001).
2. Crowe, S.R., Miller, S.C. & Woodland, D.L. Identification of protective and non-protective T cell epitopes in influenza. Vaccine 24, 452-456 (2006).
3. Diamond, D.J., York, J., Sun, J.Y., Wright, C.L. & Forman, S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90, 1751-1767 (1997).
4. Larche, M. & Wraith, D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69-S76 (2005).
5. BenMohamed, L., Wechsler, S.L. & Nesburn, A.B. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2, 425-431 (2002).
6. Fonseca, D.P., Joosten, D., Snippe, H. & Verheul, A.F. Evaluation of Tcell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis. Mol. Immunol. 37, 413-422 (2000).
7. Pialoux, G. et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 15, 1239-1249 (2001).
8. Livingston, B.D. et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159, 1383-1392 (1997).
9. Vitiello, A. et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95, 341-349 (1995).
10. Doolan, D.L. et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 165, 1123-1137 (2000).
11. Sidney, J. et al. Several HLA alleles share overlapping peptide specificities. J. Immunol. 154, 247-259 (1995).
12. De Groot, A.S. & Moise, L. New tools, new approaches and new ideas for vaccine development. Expert Rev. Vaccines 6, 125-127 (2007).
13. Sette, A. & Fikes, J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15, 461-470 (2003).
14. Herr, W. et al. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc. Natl. Acad. Sci. USA 96, 12033-12038 (1999).
15. Meiring, H.D. et al. Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+ lymphocytes. J. Immunol. 174, 5636-5643 (2005).
16. + cytotoxic T lymphocytes. J. Clin. Invest. 97, 577-584 (1996).
17. Tsomides, T.J. et al. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J. Exp. Med. 180, 1283-1293 (1994).
18. van Els, C.A. et al. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur. J. Immunol. 30, 1172-1181 (2000).
19. Johnson, K.L., Ovsyannikova, I.G., Madden, B.J., Poland, G.A. & Muddiman, D.C. Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. J. Am. Soc. Mass Spectrom. 16, 1812-1817 (2005).
20. Yewdell, J.W. & Del Val, M. Immunodominance in TCD8+ responses to viruses: cell biology, cellular immunology, and mathematical models. Immunity 21, 149-153 (2004).
21. +-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product. Infect. Immun. 70, 2926-2932 (2002).
22. Ovsyannikova, I.G., Johnson, K.L., Muddiman, D.C., Vierkant, R.A. & Poland, G.A. Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides. J. Virol. 78, 42-51 (2004).
23. Moutaftsi, M. et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat. Biotechnol. 24, 817-819 (2006).
24. Perkins, D.L., Lai, M.Z., Smith, J.A. & Gefter, M.L. Identical peptides recognized by MHC class I- and II-restricted T cells. J. Exp. Med. 170, 279-289 (1989).
25. Hickling, J.K., Fenton, C.M., Howland, K., Marsh, S.G. & Rothbard, J.B. Peptides recognized by class I restricted T cells also bind to MHC class II molecules. Int. Immunol. 2, 435-441 (1990).
26. Sette, A. et al. Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules. J. Immunol. 147, 3893-3900 (1991).
27. Ota, M.O. et al. Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. J. Infect. Dis. 195, 1799-1807 (2007).
28. Johnson, K.L., Ovsyannikova, I.G., Poland, G. & Muddiman, D.C. Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry. J. Proteome Res. 4, 2243-2249 (2005).
29. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G. & Rammensee, H.-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296 (1991).
30. Hunt, D.F. et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255, 1261-1263 (1992).
31. d. Science 256, 1817-1820 (1992).
32. Purcell, A.W. & Gorman, J.J. Immunoproteomics: mass spectrometry-based methods to study the targets of the immune response. Mol. Cell. Proteomics 3, 193-208 (2004).
33. Engelhard, V.H. The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes. Int. J. Mass Spectrom. 259, 32-39 (2007).
34. Hernandez, P., Muller, M. & Appel, R.D. Automated protein identification by tandem mass spectrometry: issues and strategies. Mass Spectrom. Rev. 25, 235-254 (2006).
35. Covert, B.A., Spencer, J.S., Orme, I.M. & Belisle, J.T. The application of proteomics in defining the T cell antigens of Mycobacterium tuberculosis. Proteomics 1, 574-586 (2001).
36. Rodriguez-Ortega, M.J. et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat. Biotechnol. 24, 191-197 (2006).
37. Weinzierl, A.O. et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell. Proteomics 6, 102-113 (2007).
38. Meiring, H.D. et al. Stable isotope tagging of epitopes: a highly selective strategy for the identification of major histocompatibility complex class I-associated peptides induced upon viral infection. Mol. Cell. Proteomics 5, 902-913 (2006).
39. Zubarev, R.A. et al. Electron capture dissociation for structural characterization of multiply charged protein cations. Anal. Chem. 72, 563-573 (2000).
40. Shi, S.D., Hendrickson, C.L. & Marshall, A.G. Counting individual sulfur atoms in a protein by ultrahigh-resolution Fourier transform ion cyclotron resonance mass spectrometry: experimental resolution of isotopic fine structure in proteins. Proc. Natl. Acad. Sci. USA 95, 11532-11537 (1998).
41. Jensen, P.K. et al. Probing proteomes using capillary isoelectric focusing-electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal. Chem. 71, 2076-2084 (1999).
42. Stump, M.J., Jones, J.J., Fleming, R.C., Lay, J.O. Jr. & Wilkins, C.L. Use of double-depleted 13C and 15N culture media for analysis of whole cell bacteria by MALDI time-of-flight and Fourier transform mass spectrometry. J. Am. Soc. Mass Spectrom. 14, 1306-1314 (2003).
43. Xiong, Y., Schroeder, K., Greenbaum, N.L., Hendrickson, C.L. & Marshall, A.G. Improved mass analysis of oligoribonucleotides by 13C, 15N double depletion and electrospray ionization FT-ICR mass spectrometry. Anal. Chem. 76, 1804-1809 (2004).
44. Lemmel, C. et al. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22, 450-454 (2004).
45. Hogan, K.T. et al. Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol. Immunother. 54, 359-371 (2005).
46. Sette, A. et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31, 813-822 (1994).
47. Sette, A. et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592 (1994).
48. Sette, A. et al. Isolation and characterization of naturally processed peptides bound by class II molecules and peptides presented by normal and mutant antigen-presenting cells. Chem. Immunol. 57, 152-165 (1993).
49. Crotzer, V.L. et al. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J. Immunol. 164, 6120-6129 (2000).
50. Christinck, E.R., Luscher, M.A., Barber, B.H. & Williams, D.B. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352, 67-70 (1991).
51. Demotz, S., Grey, H.M. & Sette, A. The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 249, 1028-1030 (1990).
52. Harding, C.V. & Unanue, E.R. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 346, 574-576 (1990).
53. Malmstrom, J. et al. Optimized peptide separation and identification for mass spectrometry based proteomics via free-flow electrophoresis. J. Proteome Res. 5, 2241-2249 (2006).
54. Krijgsveld, J., Gauci, S., Dormeyer, W. & Heck, A.J. In-gel isoelectric focusing of peptides as a tool for improved protein identification. J. Proteome Res. 5, 1721-1730 (2006).
55. Essader, A.S., Cargile, B.J., Bundy, J.L. & Stephenson, J.L. Jr. A comparison of immobilized pH gradient isoelectric focusing and strong-cation-exchange chromatography as a first dimension in shotgun proteomics. Proteomics 5, 24-34 (2005).
56. Brockman, A.H., Orlando, R. & Tarleton, R.L. A new liquid chromatography/tandem mass spectrometric approach for the identification of class I major histocompatibility complex-associated peptides that eliminates the need for bioassays. Rapid Commun. Mass Spectrom. 13, 1024-1030 (1999).
57. Zarling, A.L. et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 103, 14889-14894 (2006).
58. Meadows, L. et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6, 273-281 (1997).
59. Parker, K.C., Bednarek, M.A. & Coligan, J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175 (1994).
60. Rammensee, H.-G., Bachmann, J., Emmerich, N.P.N., Bachor, O.A. & Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219 (1999).
61. Nielsen, M. et al. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 20, 1388-1397 (2004).
62. Peters, B. & Sette, A. Integrating epitope data into the emerging web of biomedical knowledge resources. Nat. Rev. Immunol. 7, 485-490 (2007).
63. Tscharke, D.C. et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201, 95-104 (2005).
64. Oseroff, C. et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc. Natl. Acad. Sci. USA 102, 13980-13985 (2005).
65. Drexler, I. et al. Identification of vaccinia virus epitope-specific HLAA* 0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. USA 100, 217-222 (2003).
66. Terajima, M. et al. Identification of vaccinia CD8(+) T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Hum. Immunol. 67, 512-520 (2006).
67. Snyder, J.T., Belyakov, I.M., Dzutsev, A., Lemonnier, F. & Berzofsky, J.A. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78, 7052-7060 (2004).
68. Hughes, S.J., Johnston, L.H., de Carlos, A. & Smith, G.L. Vaccinia virus encodes an active thymidylate kinase that complements a cdc8 mutant of Saccharomyces cerevisiae. J. Biol. Chem. 266, 20103-20109 (1991).
69. Li, P. et al. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J. Immunol. 175, 6481-6488 (2005).
70. van Binnendijk, R.S. et al. Human HLA class I- and HLA class IIrestricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein. J. Virol. 67, 2276-2284 (1993).
71. Nanan, R., Carstens, C. & Kreth, H.W. Demonstration of virus-specific CD8+ memory T cells in measles-seropositive individuals by in vitro peptide stimulation. Clin. Exp. Immunol. 102, 40-45 (1995).
72. van Els, C.A. et al. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur. J. Immunol. 30, 1172-1181 (2000).
73. Herberts, C.A. et al. A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomaldependent MHC class I processing pathway. J. Gen. Virol. 82, 2131-2142 (2001).
74. Herberts, C.A. et al. Dynamics of measles virus protein expression are reflected in the MHC class I epitope display. Mol. Immunol. 39, 567-575 (2003).
75. Jacobson, S. et al. Recognition of intracellular measles virus antigens by HLA class II restricted measles virus-specific cytotoxic T lymphocytes. Ann. NY Acad. Sci. 540, 352-353 (1988).
76. Gerlier, D. et al. Efficient MHC class II-restricted presentation of measles virus to T cells relies on its targeting to its cellular receptor human CD46 and involves an endosomal pathway. Cell Biol. Int. 18, 315-320 (1994).
77. van Binnendijk, R.S. et al. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class IIrestricted cytotoxic T cell recognition. J. Exp. Med. 176, 119-128 (1992).
78. Leopardi, R., Ilonen, J., Mattila, L. & Salmi, A.A. Effect of measles virus infection on MHC class II expression and antigen presentation in human monocytes. Cell. Immunol. 147, 388-396 (1993).
79. Muller, C.P. et al. Activation of T cells by the ragged tail of MHC class II-presented peptides of the measles virus fusion protein. Int. Immunol. 8, 445-456 (1996).
80. Demotz, S. & Péléraux, A. Processing of DR1-restricted determinants from the fusion protein of measles virus following two distinct pathways. Mol. Immunol. 33, 387-397 (1996).
81. Poland, G.A. et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 20, 430-438 (2001).
82. Ovsyannikova, I.G. et al. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22, 1914-1920 (2004).
83. Ovsyannikova, I.G., Johnson, K.L., Naylor, S., Muddiman, D.C. & Poland, G.A. Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood. Virology 312, 495-506 (2003).
84. Ovsyannikova, I.G., Poland, G.A., Easler, N.J. & Vierkant, R.A. Influence of HLA-DRB1 alleles on lymphoproliferative responses to a naturally processed and presented measles virus phosphoprotein in measles immunized individuals. Hum. Immunol. 65, 209-217 (2004).
85. Ovsyannikova, I.G., Vierkant, R.A. & Poland, G.A. Importance of HLADQ and HLA-DP polymorphisms in cytokine response to naturally processed HLA-DR-derived measles virus peptides. Vaccine 24, 5381-5389 (2006).
86. Haynes, B.F. et al. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy. Trans. Assoc. Am. Physicians 106, 33-41 (1993).
87. Ou, D., Mitchell, L.A., Décarie, D., Tingle, A.J. & Nepom, G.T. Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype. Hum. Immunol. 59, 149-157 (1998).
88. Nardin, E.H. et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182, 1486-1496 (2000).
89. Naz, R.K. & Dabir, P. Peptide vaccines against cancer, infectious diseases, and conception. Front. Biosci. 12, 1833-1844 (2007).